Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Fapon at ADLM 2025: One-stop IVD Solutions & Deepened US Commitment 2025-07-24 19:00
HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma 2025-07-23 20:36
Samsung Biologics reports second quarter 2025 financial results 2025-07-23 14:54
METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting 2025-07-22 15:52
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation 2025-07-22 10:25
CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services 2025-07-21 10:54
MFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fibrillation 2025-07-18 10:59
Co-PSMA trial: Recruitment successfully completed 2025-07-17 21:01
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate 2025-07-17 19:00
GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam 2025-07-17 13:56
SNB-101 Earns Government Backing as Promising Therapy for Small Cell Lung Cancer 2025-07-16 20:00
The 2025 Mammoth International Contest on Omics Sciences - Young Scientists Track Now Open for Hot Registration! 2025-07-16 18:12
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics 2025-07-16 18:00
Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors 2025-07-16 10:32
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer 2025-07-16 09:47
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company 2025-07-15 19:30
Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity 2025-07-15 07:00
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform 2025-07-14 15:38
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO 2025-07-14 08:00
Angel Yeast Unveils 2024 Sustainability Report, Showcasing Commitment to Green Practices and Innovation 2025-07-11 15:18
1 14 15 16 17 18 262